33
Views
27
CrossRef citations to date
0
Altmetric
Review

Novel oestrogen sulfamates: a new approach to oral hormone therapy

, &
Pages 575-589 | Published online: 23 Feb 2005

Bibliography

  • SCHWARZ S, WEBER G: Alkan- und Cycloalkansulfonatedes 17alpha-Athinylöstradiols. J. Prakt. Chem. (1970) 312:653–659.
  • GORETZLEHNER G, RUDOLF B, KLAUSCH W et al.: Orale hormonale Kontrazeption mit Deposiston. Dt. Gesundh -Wesen. (1975) 33:1553–1558.
  • GORETZLEHNER G, RUDOLF K, KLAUSCH B: Orale hor-monale Kontrazeption mit der "Wochenpille" Depo-siston. Zentralbl. Gynäkol. (1974) 96:1569–1576.
  • GUDDATH H, SCHNORR D, DORNER G et al: Die klinische Priifung von Ethinylestradiolsulfonat zur konservativen Therapie des Prostatakarzinoms. Zschr. Urol. Nephrol (1987) 80:125–133.
  • SCHWARZ S, WEBER G, KOHNER F: Sulfamate des 17 -Athinylöstradiols. Z. Chemie. (1970) 10:299–300.
  • STOLZNER W: Tierexperimenteller Beitrag zur Entwicklung estrogener Wirkstoffe. Dissertation B, Friedrich-Schiller-University Jena (1989).
  • CLAUSSEN C: Etythrocyten als Arzneimittelträger - Unter-suchungen mit ausgewählten Estrogenen zur Beladung nach oraler Gabe. Dissertation B, Martin-Luther-Universitat Halle-Wittenberg (1990).
  • ELGER W, SCHNEIDER B, TRILLER et al.: Differential ef-fects of estradiol and estrone versus estriol with re-spect to uterotropic and hepatic estrogenicity. Exp. Endocrinol. (1996) 104:18.
  • SCHWARZ S, THIEME I, RICHTER M et al.: Synthesis of es-trogen sulfamates: compounds with a novel endocri-nological profile. Steroids (1996) 61:710–717.
  • HEDDEN A, JENSEN EV, PALME HJ et al: Analysis of prodrug nature of oestradiol sulfamate (ES) J995: study of oestrogen receptor (ER) binding and induc-tion of ER synthesis in MCF-7-cells. Exp. Clin. Endocri-nol. (1998) 106.
  • KRATTENMACHER R, KNAUTHE R, PARCZYK K et al.: Es-trogen action on hepatic synthesis of angiotensinogen and IGF-I: direct and indirect estrogen effects. J. Steroid. Biochem. Mol. Biol. (1994) 48:207–214.
  • SCHNEIDER B, FRANKE E, MATZ S et al.: Orally active es-trogens with reduced effects on bile secretion and bile composition. Exp. Clin. Endocrinol. Diabetes (1997) 105:78.
  • ZUCHNER J, KRAHL E, REDDERSEN G et al.: Effects oferythrocytes on the hepatic extraction and metabo-lism of estradiol (E) and estradiol sulfamate (ES) in the perfused rat liver. Exp. Clin. Endocrinol. Diabetes (1997) 105:79.
  • JACOBSOHN GM, SIEGEL ET, JACOBSOHN MK: 17 -estr-adiol transport and metabolism in human red blood cells. J. Clin. Endocrinol Metab. (1975) 40(2):177–185.
  • KRAHL E, REDDERSEN G, MOLLER K et al.: Studies on the transhepatic transfer of oestradiol sulfamate J995 (ES) and the mechanism of systemic release of oestradiol. Exp. Clin. Endocrinol Diabetes (1996) 104:127.
  • ZIMMERMANN H, Jenapharm GmbH &Co.KG (1997). (Un-published data.)
  • HELMER OM, GRIFFITH RS: The effect of the administra-tion of estrogens on the renin-substrate (hyper-tensinogen) content on rat plasma. Endocrinology (1952) 51:421–426.
  • FREYSCHUSS B, STAVREUS-EVERS A, SAHLIN L et al.: In-duction of the oestrogen receptor by growth hormone and glucocorticoid substitution in primary cultures of rat hepatocytes. Endocrinology (1993) 133:1548–1554.
  • SAHLIN L, NORSTEDT G, ERIKSSON H: Estrogen regula-tion of the estrogen receptor and insulin-like growth factor I in the rat uterus: a potential coupling between effects of estrogen and IGF-I. Steroids (1994) 59:421–430.
  • ELGER W, SCHWARZ S, HEDDEN A et al.: Sulfamates of various estrogens are prodrugs with increased sys-temic and reduced hepatic estrogenicity at oral appli-cation. J. Steroid. Biochem. Mol. Biol. (1995) 55:395–403.
  • GOLDZIEHER JW: Selected aspects of the pharmacoki-netics and metabolism of ethinyl estrogens and their clinical implications. Am. J. Obstet. Gynecol. (1990) 163:318–322.
  • SCHOULTZ VON B, CARLSTROM K, COLLSTE L et al.: Es-trogen therapy and liver function-metabolic effects of oral and parenteral administration. The Prostate (1989) 14:389–395.
  • MASHCHAK CA, LOBO RA, DOZONO-TAKANO R et al.:Comparison of pharmacodynamic properties of vari-ous estrogen formulation. Am. J. Obstet. Gynecol (1982) 144:511–518.
  • MELAMED M, CASTANO E, NOTIDES AC et al.: Molecular and kinetic basis for the mixed agonist/antagonist ac-tivity of estriol. Mol. Endocrinol (1997) 11:1868–1878.
  • REED MJ, PUROHIT A, HOWARTH NM et al.: Steroid sul-phatase inhibitor: a new endocrine therapy. Drugs Fut. (1994) 19(7):673–680.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.